These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8057103)

  • 1. Serum concentrations of 2',5'-oligoadenylate synthetase, neopterin, and beta-glucan in patients with chronic fatigue syndrome and in patients with major depression.
    Matsuda J; Gohchi K; Gotoh N
    J Neurol Neurosurg Psychiatry; 1994 Aug; 57(8):1015-6. PubMed ID: 8057103
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C].
    Daito K; Suou T; Kawasaki H
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):981-5. PubMed ID: 7563914
    [No Abstract]   [Full Text] [Related]  

  • 3. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
    Witt PL; Spear GT; Lindstrom MJ; Kessler HA; Borden EC; Phair J; Landay AL
    AIDS; 1991 Mar; 5(3):289-93. PubMed ID: 2059368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in serum levels of beta 2-microglobulin, neopterin and 2',5'-oligoadenylate synthase activity during clearance of hepatitis B virus with or without acute phase in transaminases].
    Carreño García V; Hernández-Guío C; Bartolomé Nebreda J; Quiroga Estévez JA
    Rev Esp Enferm Dig; 1993 Mar; 83(3):169-75. PubMed ID: 7683894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and urinary neopterin levels in patients with chronic active hepatitis B treated with interferon.
    Daito K; Suou T; Kawasaki H
    Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):303-16. PubMed ID: 8008980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum neopterin and interleukin-6 levels in chronic fatigue syndrome.
    Chao CC; Gallagher M; Phair J; Peterson PK
    J Infect Dis; 1990 Dec; 162(6):1412-3. PubMed ID: 2230278
    [No Abstract]   [Full Text] [Related]  

  • 7. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
    J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
    Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
    J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome.
    Vojdani A; Choppa PC; Lapp CW
    J Clin Lab Immunol; 1998; 50(1):1-16. PubMed ID: 10189612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
    Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
    Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
    Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
    Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.
    Boccoli G; Masciulli R; Ruggeri EM; Carlini P; Giannella G; Montesoro E; Mastroberardino G; Isacchi G; Testa U; Calabresi F
    Cancer Res; 1990 Sep; 50(18):5795-800. PubMed ID: 2118421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/IB study of polyadenylic-polyuridylic acid in patients with advanced malignancies: clinical and biologic effects.
    Witt PL; Zahir S; Ritch PS; McAuliffe TM; Ewel CH; Borden EC
    J Interferon Cytokine Res; 1996 Aug; 16(8):631-5. PubMed ID: 8877734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.
    Liberati AM; Garofani P; De Angelis V; Di Clemente F; Horisberger M; Cecchini M; Betti AR; Palmisano L; Astolfi S; Nastari A
    J Interferon Res; 1994 Apr; 14(2):61-9. PubMed ID: 8077767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease.
    Davidsen B; Munkholm P; Schlichting P; Nielsen OH; Krarup H; Bonnevie-Nielsen V
    Aliment Pharmacol Ther; 1995 Feb; 9(1):75-9. PubMed ID: 7766748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
    Yang PM; Wang JT; Chiang BL; Lai MY; Chen DS
    J Formos Med Assoc; 1997 May; 96(5):314-9. PubMed ID: 9170817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [2-5 oligoadenylate synthetase].
    Koura T; Kaneko S; Kobayashi K; Kato Y
    Nihon Rinsho; 1999 Sep; 57 Suppl():794-6. PubMed ID: 10543239
    [No Abstract]   [Full Text] [Related]  

  • 19. [2-5 Oligoadenylate synthetase].
    Koura T; Kato Y; Unoura M
    Nihon Rinsho; 1995 Mar; 53 Su Pt 2():202-5. PubMed ID: 8753217
    [No Abstract]   [Full Text] [Related]  

  • 20. [Overview of our patients with chronic fatigue syndrome (CFS) from the pathoetiological aspects].
    Matsuda J; Gohchi K
    Nihon Rinsho; 1992 Nov; 50(11):2635-40. PubMed ID: 1287240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.